{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:14:01Z","timestamp":1757700841094,"version":"3.41.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.vaccine.2016.12.003","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T14:41:06Z","timestamp":1482417666000},"page":"655-662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine"],"prefix":"10.1016","volume":"35","author":[{"given":"M.","family":"Rissmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hammerschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mroz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.H.","family":"Groschup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.12.003_b0005","first-page":"8","article-title":"Molecular biology of rift valley Fever virus","volume":"4","author":"Bouloy","year":"2010","journal-title":"Open Virol J"},{"key":"10.1016\/j.vaccine.2016.12.003_b0010","first-page":"19506","article-title":"Rift Valley fever\u2013a threat for Europe? Euro surveillance: bulletin Europeen sur les maladies transmissibles =","volume":"15","author":"Chevalier","year":"2010","journal-title":"Eur Communicable Dis Bull"},{"key":"10.1016\/j.vaccine.2016.12.003_b0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1051\/vetres\/2010033","article-title":"Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention","volume":"41","author":"Pepin","year":"2010","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2016.12.003_b0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2004.09.018","article-title":"Ocular complications of Rift Valley fever outbreak in Saudi Arabia","volume":"112","author":"Al-Hazmi","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.vaccine.2016.12.003_b0025","doi-asserted-by":"crossref","first-page":"e0003548","DOI":"10.1371\/journal.pntd.0003548","article-title":"Factors associated with severe human Rift Valley fever in Sangailu, Garissa County, Kenya","volume":"9","author":"LaBeaud","year":"2015","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.vaccine.2016.12.003_b0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2460\/javma.234.7.883","article-title":"Rift Valley fever virus","volume":"234","author":"Bird","year":"2009","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2016.12.003_b0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/path.1700860131","article-title":"Rift Valley fever in camels","volume":"86","author":"Scott","year":"1963","journal-title":"J Pathol Bacteriol"},{"key":"10.1016\/j.vaccine.2016.12.003_b0040","doi-asserted-by":"crossref","first-page":"e66626","DOI":"10.1371\/journal.pone.0066626","article-title":"Rift Valley fever risk map model and seroprevalence in selected wild ungulates and camels from Kenya","volume":"8","author":"Britch","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.003_b0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1017\/S0022172400061441","article-title":"Rift Valley fever in Kenya: the presence of antibody to the virus in camels (Camelus dromedarius)","volume":"94","author":"Davies","year":"1985","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2016.12.003_b0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11250-014-0726-y","article-title":"Seroprevalence of Rift Valley fever virus infection in camels (dromedaries) in northern Tanzania","volume":"47","author":"Swai","year":"2015","journal-title":"Trop Anim Health Prod"},{"key":"10.1016\/j.vaccine.2016.12.003_b0055","doi-asserted-by":"crossref","first-page":"741","DOI":"10.20506\/rst.18.3.1195","article-title":"An epizootic of Rift Valley fever in Egypt in 1997","volume":"18","author":"Abd el-Rahim","year":"1999","journal-title":"Revue Sci Techn (Int Office Epizootics)"},{"key":"10.1016\/j.vaccine.2016.12.003_b0060","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/0035-9203(79)90005-1","article-title":"The Rift Valley fever epizootic in Egypt 1977\u201378. 2. Ecological and entomological studies","volume":"73","author":"Hoogstraal","year":"1979","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2016.12.003_b0065","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3201\/eid1710.110397","article-title":"Unexpected Rift Valley fever outbreak, northern Mauritania","volume":"17","author":"El Mamy","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.003_b0070","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12917-016-0775-8","article-title":"Safety and immunogenecity of a live attenuated Rift Valley fever vaccine (CL13T) in camels","volume":"12","author":"Daouam","year":"2016","journal-title":"BMC Vet Res"},{"key":"10.1016\/j.vaccine.2016.12.003_b0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2014.03.008","article-title":"One Health approach to Rift Valley fever vaccine development","volume":"106","author":"Kortekaas","year":"2014","journal-title":"Antiviral Res"},{"issue":"Pt 10","key":"10.1016\/j.vaccine.2016.12.003_b0080","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.12.003_b0085","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2460\/ajvr.1991.52.01.50","article-title":"Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever","volume":"52","author":"Hubbard","year":"1991","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2016.12.003_b0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.003_b0095","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2460\/ajvr.1987.48.07.1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes","volume":"48","author":"Morrill","year":"1987","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2016.12.003_b0100","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","article-title":"Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2016.12.003_b0105","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/S0264-410X(03)00131-2","article-title":"Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys","volume":"21","author":"Morrill","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.003_b0110","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine Phase 2 clinical trial: safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.003_b0115","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep","volume":"69","author":"Hunter","year":"2002","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2016.12.003_b0120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vetmic.2014.04.007","article-title":"Evaluation of lamb and calf responses to Rift Valley fever MP-12 vaccination","volume":"172","author":"Wilson","year":"2014","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2016.12.003_b0125","unstructured":"OIE. OIE Terrestrial Manual 2014. Manual of diagnostic tests and vaccines for terrestrial animals; 2008. [chapter 2.1.14 \u2013 Rift Valley fever]."},{"key":"10.1016\/j.vaccine.2016.12.003_b0130","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/104063879801000210","article-title":"Normal reference intervals and the effects of time and feeding on serum bile acid concentrations in llamas","volume":"10","author":"Andreasen","year":"1998","journal-title":"J Vet Diagn Invest"},{"key":"10.1016\/j.vaccine.2016.12.003_b0135","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.2460\/ajvr.1989.50.12.2049","article-title":"Reference ranges for hematologic and serum biochemical values in llamas (Lama glama)","volume":"50","author":"Fowler","year":"1989","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2016.12.003_b0140","doi-asserted-by":"crossref","first-page":"e16142","DOI":"10.1371\/journal.pone.0016142","article-title":"RNA and DNA bacteriophages as molecular diagnosis controls in clinical virology: a comprehensive study of more than 45,000 routine PCR tests","volume":"6","author":"Ninove","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.003_b0145","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1128\/JCM.00936-07","article-title":"Highly sensitive and broadly reactive quantitative reverse transcription-PCR assay for high-throughput detection of Rift Valley fever virus","volume":"45","author":"Bird","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2016.12.003_b0150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/tbed.12142","article-title":"Molecular and serological studies on the Rift Valley fever outbreak in Mauritania in 2010","volume":"60","author":"Jackel","year":"2013","journal-title":"Transboundary Emerg Dis"},{"key":"10.1016\/j.vaccine.2016.12.003_b0155","doi-asserted-by":"crossref","first-page":"e0004779","DOI":"10.1371\/journal.pntd.0004779","article-title":"Spatio-temporal analysis of the genetic diversity of arctic rabies viruses and their reservoir hosts in Greenland","volume":"10","author":"Hanke","year":"2016","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.vaccine.2016.12.003_b0160","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00705-013-1867-4","article-title":"Generation and application of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein NP and glycoproteins Gn and Gc","volume":"159","author":"Jackel","year":"2014","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2016.12.003_b0165","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","article-title":"Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience","volume":"18","author":"Pittman","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.003_b0170","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/CVI.00114-15","article-title":"Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated Rift Valley fever virus vaccine candidate, in sheep","volume":"22","author":"Miller","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.12.003_b0175","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/vbz.2014.1721","article-title":"Multiplex detection of IgG and IgM to Rift Valley fever virus nucleoprotein, nonstructural proteins, and glycoprotein in ovine and bovine","volume":"16","author":"Hossain","year":"2016","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.vaccine.2016.12.003_b0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/infdis\/121.1.9","article-title":"The clinical aspects of Rift Valley Fever virus in household pets. I. Susceptibility of the dog","volume":"121","author":"Walker","year":"1970","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.003_b0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/infdis\/121.1.19","article-title":"The clinical aspects of Rift Valley Fever virus in household pets. II. Susceptibility of the cat","volume":"121","author":"Walker","year":"1970","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.003_b0190","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4269\/ajtmh.1991.44.278","article-title":"Potential for mosquito transmission of attenuated strains of Rift Valley fever virus","volume":"44","author":"Turell","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2016.12.003_b0195","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1128\/JVI.79.18.12106-12111.2005","article-title":"Rift Valley fever virus NSs mRNA is transcribed from an incoming anti-viral-sense S RNA segment","volume":"79","author":"Ikegami","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.12.003_b0200","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1128\/JVI.74.3.1538-1543.2000","article-title":"The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice","volume":"74","author":"Vialat","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.12.003_b0205","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.1128\/JVI.00135-15","article-title":"Rift Valley fever virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the S, M, and L segments","volume":"89","author":"Ikegami","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.12.003_b0210","doi-asserted-by":"crossref","unstructured":"Nishiyama S, Lokugamage N, Ikegami T. The L, M, and S segments of Rift Valley fever virus MP-12 vaccine independently contribute to a temperature-sensitive phenotype. J Virol. 2016;90:3735-44.","DOI":"10.1128\/JVI.02241-15"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16311975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16311975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T20:28:30Z","timestamp":1749846510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16311975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0264410X16311975"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}